Study says Alcohol may impact atrial fibrillation | Atrial Fibrillation News andhrawishesh.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from andhrawishesh.com Daily Mail and Mail on Sunday newspapers.
AI Derived Cardiac Echo Measurements Able to Predict COVID-19 Mortality
Using artificial intelligence for LVEF and longitudinal strain minimized variability compared to human review in late-breaking ACC study
The WASE-COVID Study used the artificial intelligence automated echocardiogram reading software EchoGo-Core from Ultromics to evaluate ejection fraction and left ventricle longitudinal strain in COVID-19 patients to identify risk markers for mortality. The study also compared human vs. AI variability in assessing the exams.
May 18, 2021 Artificial intelligence (AI) derived heart measurements were able to predict COVID-19 (SARS-CoV-2) mortality on echocardiograms in an international cardiac ultrasound study of COVID-19 patients. The Echocardiographic Correlates of in-hospital Death in Patients with Acute COVID-19 Infection: The World Alliance Societies of Echocardiography (WASE-COVID) Study was presented at the American College of Cardiology (ACC) 2021 virtual Scientific S
email article
Invasive resuscitation therapy and moderate cooling after resuscitation both missed the mark in clinical trials, highlighting opportunities for improvement in prehospital and hospital care for out-of-hospital cardiac arrest (OHCA).
A hyperinvasive approach to refractory OHCA featuring early transport to hospital under mechanical CPR, extracorporeal CPR (venoarterial extracorporeal membrane oxygenation [VA ECMO]), and immediate invasive evaluation was not significantly better than standard advanced cardiovascular life support, according to the Prague OHCA study, which had nevertheless been stopped prematurely due to benefit shown in secondary outcomes.
In CAPITAL CHILL, the colder of two target temperatures in therapeutic hypothermia did not improve outcomes for comatose survivors of OHCA, and in fact were associated with harm.
Will the COVID-19 pandemic have long-term effects on clinicians?
A survey of cardiologists and cardiovascular team members, conducted in November 2020, suggested that the prevalence of professional burnout nearly doubled during local COVID-19 surges. Just under a quarter of respondents had reported plans to reduce clinical work hours in 2021.
Half of the 1,288 survey respondents reported having provided direct care to COVID-19 patients. One in five said they did so without having adequate personal protective equipment, a group that was particularly prone to burnout.
Results of this and other studies were featured at this year s virtual meeting of the American College of Cardiology. The following are some of the highlights.
Sotagliflozin reduces adverse cardiovascular events across patients with diabetes, heart failure
Patients with both diabetes and heart failure who were treated with sotagliflozin, a novel investigational drug for diabetes, for a median of nine to 16 months experienced reductions of 22% to 43% in the risk of death or worsening heart failure compared with similar patients who were treated with a placebo.
The drug was effective in patients with all forms of heart failure, including those whose heart muscle is abnormally stiff (preserved ejection fraction) and for whom there is currently no effective treatment, according to research presented at the American College of Cardiology s 70th Annual Scientific Session.